Race and Gender Differences in the Use of Direct Acting Antiviral Agents for Hepatitis C Virus

Clinical Infectious Diseases

Volumn 63, Issue 3, 2016, Pages 291-299

  Kanwal, Fasiha ^a,b,c   Kramer, Jennifer R ^a,c   El Serag, Hashem B ^a,b,c   Frayne, Susan ^d   Clark, Jack ^e,f   Cao, Yumei ^a   Taylor, Thomas ^d   Smith, Donna ^a   White, Donna ^a,c   Asch, Steven M ^d  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Section of Gastroenterology and Hepatology   (United States)

^c Section of Health Services Research   (United States)

^d VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f BOSTON UNIVERSITY   (United States)

Author keywords

access; healthcare disparities; hepatitis; quality; Veterans

Indexed keywords

ANTIVIRUS AGENT; BOCEPREVIR; DIRECT ACTING ANTIVIRAL AGENT; LEDIPASVIR; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; UNCLASSIFIED DRUG;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BLACK PERSON; CAUCASIAN; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG USE; EVALUATION STUDY; FEMALE; HEALTH CARE DISPARITY; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HEPATITIS C; HISPANIC; HOMELESSNESS; HUMAN; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; RACE DIFFERENCE; SEX DIFFERENCE; SOCIAL STATUS; AFRICAN AMERICAN; AGED; DRUG EFFECTS; ETHNOLOGY; GOVERNMENT; HEPACIVIRUS; SEX FACTOR; UNITED STATES;

AFRICAN AMERICANS; AGED; ANTIVIRAL AGENTS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTHCARE DISPARITIES; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; SEX FACTORS; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS;

EID: 84981249363     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw249     Document Type: Article

References (31)

1. Sussman NL, Remien CH, Kanwal F. The end of hepatitis C. Clin Gastroenterol Hepatol 2014; 12:533-6.
2. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370:1889-98.
3. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370:1483-93.
4. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/rombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370:1594-603.
5. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370:1983-92.
6. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879-88.
7. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370:1973-82.
8. Jha AK, Fisher ES, Li Z, Orav EJ, Epstein AM. Racial trends in the use of major procedures among the elderly. N Engl J Med 2005; 353:683-91.
9. Peterson ED, Wright SM, Daley J, Thibault GE. Racial variation in cardiac procedure use and survival following acute myocardial infarction in the Department of Veterans Affairs. JAMA 1994; 271:1175-80.
10. Kanwal F, Hoang T, Spiegel BM, et al. Predictors of treatment in patients with chronic hepatitis C infection-role of patient versus nonpatient factors. Hepatology 2007; 46:1741-9.
11. Rousseau CM, Ioannou GN, Todd-Stenberg JA, et al. Racial differences in the evaluation and treatment of hepatitis C among veterans: a retrospective cohort study. Am J Public Health 2008; 98:846-52.
12. Grebely J, Bryant J, Hull P, et al. Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia. J Viral Hepat 2011; 18:e104-16.
13. Temple-Smith M, Gifford S, Stoov EM. The lived experience of men and women with hepatitis C: implications for support needs and health information. Aust Health Rev 2004; 27:46-56.
14. Ge D, Fellay J, Thompson A, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401.
15. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon- alpha and ribavirin therapy. Nat Genet 2009; 41:1100-4.
16. Kramer JR, Kanwal F, Richardson P, Giordano TP, Petersen LA, El-Serag HB. Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study. Am J Gastroenterol 2011; 106:483-91.
17. Ioannou GN, Beste LA, Green PK. Similar effectiveness of boceprevir and telaprevir treatment regimens for hepatitis C virus infection on the basis of a nationwide study of veterans. Clin Gastroenterol Hepatol 2014; 12:1371-80.
18. Kanwal F, Hoang T, Kramer J, et al. The performance of process measures in hepatitis C. Am J Gastroenterol 2012; 107:1512-21.
19. Wu S, Crespi CM, Wong WK. Comparison of methods for estimating the intraclass correlation coefficient for binary responses in cancer prevention cluster randomized trials. Contemp Clin Trials 2012; 33:869-80.
20. Wood S.N. Stable and efficient multiple smoothing parameter estimation for generalized additive models. J Am Stat Assoc 2004; 99:673-86.
21. Buckle JM, Horn SD, Oates VM, Abbey H. Severity of illness and resource use differences among white and AA hospitalized elderly. Arch Intern Med 1992; 152:1596-603.
22. Carlisle DM, Leake BD, Shapiro MF. Racial and ethnic disparities in the use of cardiovascular procedures: associations with type of health insurance. Am J Public Health 1997; 87:263-7.
23. Eggers PW. Racial differences in access to kidney transplantation. Health Care Financ Rev 1995; 17:89-103.
24. Escarce JJ, Epstein KR, Colby DC, Schwartz JS. Racial differences in the elderly's use of medical procedures and diagnostic tests. Am J Public Health 1993; 83:948-54.
25. Greenwald HP, Polissar NL, Borgatta EF, McCorkle R, Goodman G. Social factors, treatment, and survival in early-stage non-small cell lung cancer. Am J Public Health 1998; 88:1681-4.
26. Moore RD, Stanton D, Gopalan R, Chaisson RE. Racial differences in the use of drug therapy for HIV disease in an urban community. N Engl J Med 1994; 330:763-8.
27. Yergan J, Flood AB, LoGerfo JP, Diehr P. Relationship between patient race and the intensity of hospital services. Med Care 1987; 25:592-603.
28. Yoon J, Scott JY, Phibbs CS, Frayne SM. Trends in rates and attributable costs of conditions among female VA patients, 2000 and 2008. Womens Health Issues 2012; 22:e337-44.
29. Armed Forces Health Surveillance Center (AFHSC). Surveillance snapshot: service members with hepatitis B, hepatitis C, and HIV-1, active component, U.S. Armed Forces. MSMR 2011; 18:23.
30. Jha AK, Shlipak MG, Hosmer W, Frances CD, Browner WS. Racial differences in mortality among men hospitalized in the Veterans Affairs health care system. JAMA 2001; 285:297-303.
31. Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med 2013; 158:807-20.